Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

11 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02239393 (ClinicalTrials.gov)	June 2015	10/9/2014	Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study	MEsenchymal Stem Cell Therapy for CAnadian MS Patients	Multiple Sclerosis	Biological: Mesenchymal Stem Cells	Ottawa Hospital Research Institute	NULL	Completed	18 Years	50 Years	All	31	Phase 2	Canada
2	NCT02495766 (ClinicalTrials.gov)	May 11, 2015	3/6/2015	Autologous Mesenchymal Stromal Cells for Multiple Sclerosis	Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: XCEL-MC-ALPHA;Drug: Placebo	Banc de Sang i Teixits	Vall d'Hebron Research Institute (VHIR)	Completed	18 Years	60 Years	All	8	Phase 1/Phase 2	Spain
3	EUCTR2012-000734-19-ES (EUCTR)	10/04/2014	10/01/2014	Bone marrow cell treatment as treatment of multiple sclerosis	Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES	Multiple Sclerosis MedDRA version: 16.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: XCEL-MC-ALPHA Product Code: XCEL-MC-ALPHA INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved Other descriptive name: Mesenchymal Stem Cells	Banc de Sang i Teixits	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Spain
4	NCT02035514 (ClinicalTrials.gov)	December 2013	17/12/2013	Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis	Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS)	Biological: Bone marrow autologous mesenchymal stem cells transplantation	Germans Trias i Pujol Hospital	Ministerio de Sanidad, Servicios Sociales e Igualdad	Completed	18 Years	50 Years	Both	9	Phase 1/Phase 2	Spain
5	NCT01730547 (ClinicalTrials.gov)	February 2013	9/11/2012	Mesenchymal Stem Cells for Multiple Sclerosis	Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous mesenchymal stem cells	Karolinska Institutet	NULL	Recruiting	18 Years	50 Years	Both	15	Phase 1/Phase 2	Sweden
6	NCT02249676 (ClinicalTrials.gov)	January 2013	15/9/2014	Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders	Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study	Devic's Syndrome;Devic's Neuromyelitis Optica;Devic Syndrome;Devic's Disease;Devic Disease	Biological: Autologous mesenchymal stem cells	Tianjin Medical University General Hospital	NULL	Completed	18 Years	80 Years	All	15	Phase 2	China
7	NCT03778333 (ClinicalTrials.gov)	December 1, 2012	14/1/2015	Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden	Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden	Autologous Mesenchymal Stem Cells;Multiple Sclerosis	Biological: Autologous mesenchymal stem cells	Karolinska Institutet	NULL	Completed	18 Years	65 Years	All	7	Phase 1	Sweden
8	NCT01895439 (ClinicalTrials.gov)	October 2012	24/6/2013	Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis	Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment	Multiple Sclerosis	Biological: Autologous Mesenchymal Stem Cells	University of Jordan	NULL	Completed	18 Years	65 Years	All	13	Phase 1/Phase 2	Jordan
9	NCT01854957 (ClinicalTrials.gov)	July 2012	8/5/2013	MEsenchymal StEm Cells for Multiple Sclerosis	MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous Mesenchymal Stem Cells	Antonio Uccelli	Azienda Ospedaliera Universitaria Integrata Verona;Ospedale San Raffaele	Recruiting	18 Years	50 Years	Both	20	Phase 1/Phase 2	Italy
10	NCT01228266 (ClinicalTrials.gov)	December 2010	25/10/2010	Mesenchymal Stem Cell Transplantation in MS	Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study	Multiple Sclerosis	Biological: autologous mesenchymal stem cells	Albert Saiz	Instituto de Salud Carlos III	Terminated	18 Years	50 Years	Both	9	Phase 2	Spain
11	EUCTR2015-000137-78-AT (EUCTR)		17/09/2015	Mesenchymal stem cells therapy for patients with multiple sclerosis	Randomised, double-blind, cross-over phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria)	multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Human autologous mesenchymal stem cells INN or Proposed INN: MSC2015 Other descriptive name: UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS	SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMU	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Austria

先頭へ